Search research articles
Contact Us
Filters
Showing results (371-380 of 516) with videos related to
Page
of 52
Sort By:
American Journal of Hematology
|
February 25, 2026
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and Dexamethasone
Ricardo D Parrondo, Ricardo C B de Menezes, Hanna Sledge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Rahul Banerjee, Matthew C Cheung, Benjamin Derman, et al.
Blood Cancer Journal
|
April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
Shaji Kumar, Katja C Weisel, Paul Spin, et al.
American Journal of Hematology
|
December 17, 2019
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity
Marcella Tschautscher, Dragan Jevremovic, Francis K Buadi, et al.
Cancer Medicine
|
October 6, 2020
Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment
Iuliana Vaxman, Abdullah S Al Saleh, Shaji Kumar, et al.
American Journal of Hematology
|
December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Jonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
British Journal of Haematology
|
June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma
Jithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
American Journal of Hematology
|
January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Mayo Clinic Proceedings
|
March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
Angela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology
|
July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
Francesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Page
of 52
Search research articles
Search
Showing results (371-380 of 516) with videos related to
Sort By:
Page
of 52
American Journal of Hematology
|
February 25, 2026
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated With Front-Line Daratumumab Lenalidomide and Dexamethasone
Ricardo D Parrondo, Ricardo C B de Menezes, Hanna Sledge, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 20, 2026
Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1
Rahul Banerjee, Matthew C Cheung, Benjamin Derman, et al.
Blood Cancer Journal
|
April 1, 2026
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States
Shaji Kumar, Katja C Weisel, Paul Spin, et al.
American Journal of Hematology
|
December 17, 2019
Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity
Marcella Tschautscher, Dragan Jevremovic, Francis K Buadi, et al.
Cancer Medicine
|
October 6, 2020
Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment
Iuliana Vaxman, Abdullah S Al Saleh, Shaji Kumar, et al.
American Journal of Hematology
|
December 28, 2020
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Jonathan L Kaufman, Cristina Gasparetto, Fredrik H Schjesvold, et al.
British Journal of Haematology
|
June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma
Jithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
American Journal of Hematology
|
January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival
Charalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Mayo Clinic Proceedings
|
March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
Angela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology
|
July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma
Francesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
Page
of 52